The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

Cipla's product portfolio spans complex generics as well as drugs in the respiratory anti-retroviral urology cardiolo... In compliance with regulation 30 of SEBI (Listing Obligations and Disclosure ...

Cipla is currently valued at Rs 1480.00, indicating a daily change of 1.09%. The 5-day exponential moving average stands at Rs 1470.50. Cipla is currently trading at Rs 1477.7, reflecting a positive ...

Stocks like CIE Automotive India, Sanofi Consumer Healthcare, Delta Corp, Mahindra and Mahindra, Grindwell Norton, Keystone ...

Dr Reddy's, Zydus Lifesciences,... Feb 19, 2025 19:23 Cipla Q3 Profit Surges 49% to Rs 1,571 Crore Cipla's net profit for Q3 FY25 jumped 49% to Rs 1,571 crore, driven by growth across markets. Revenue ...

Cipla finished the day at Rs 1464.15, showing a fall of 1.22% in its market value. Cipla's shares are currently priced at Rs 1465.95, reflecting a 1.09% decrease today, alongside a return of 3.38% ...

Union Power Minister urges industry to innovate and make the power sector a growth engine for India's economy. Elecrama 2025 focuses on renewable energy, smart grid solutions, and EV charging... Feb ...

And how much does it really cost to bring a drug to market? Increasingly, though, these debates are happening when everyone knows that the list price is not the ‘real’ price to be paid ...

Despite successful models in a few parts of India where regulated access to opioids has been implemented safely, there ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

Reddy's, like other Indian drugmakers, is banking on yet to be launched generic weight-loss drugs for growth over the next few years in the U.S. CIPLA (CIPL.NS), opens new tab India's third ...